Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 559

1.

Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn's disease.

Chateau T, Angioi K, Peyrin-Biroulet L.

J Crohns Colitis. 2019 Oct 14. pii: jjz167. doi: 10.1093/ecco-jcc/jjz167. [Epub ahead of print] No abstract available.

PMID:
31606743
2.

Application of Artificial Intelligence to Gastroenterology and Hepatology.

Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L.

Gastroenterology. 2019 Oct 5. pii: S0016-5085(19)41412-1. doi: 10.1053/j.gastro.2019.08.058. [Epub ahead of print] Review.

PMID:
31593701
3.

Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases?

Chateau T, Le Berre C, Peyrin-Biroulet L.

Clin Gastroenterol Hepatol. 2019 Oct 4. pii: S1542-3565(19)31085-7. doi: 10.1016/j.cgh.2019.09.036. [Epub ahead of print] No abstract available.

PMID:
31589974
4.

Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases.

Kotze PG, Peyrin-Biroulet L, Danese S.

Curr Drug Targets. 2019;20(13):1315-1316. doi: 10.2174/138945012013190902150906.

PMID:
31556358
5.

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group.

N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.

PMID:
31553834
6.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group.

N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.

PMID:
31553833
7.

Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review.

Estevinho MM, Rocha C, Correia L, Lago P, Ministro P, Portela F, Trindade E, Afonso J, Peyrin-Biroulet L, Magro F; GEDII (Portuguese IBD Group).

Clin Gastroenterol Hepatol. 2019 Sep 14. pii: S1542-3565(19)31003-1. doi: 10.1016/j.cgh.2019.08.063. [Epub ahead of print] Review.

PMID:
31526845
8.

Evolving therapeutic goals in ulcerative colitis: towards disease clearance.

Danese S, Roda G, Peyrin-Biroulet L.

Nat Rev Gastroenterol Hepatol. 2019 Sep 13. doi: 10.1038/s41575-019-0211-1. [Epub ahead of print] No abstract available.

PMID:
31520081
9.

Environmental, Nutritional and Socio-Economic Determinants of IBD Incidence: A Global Ecological Study.

Piovani D, Danese S, Peyrin-Biroulet L, Bonovas S.

J Crohns Colitis. 2019 Aug 29. pii: jjz150. doi: 10.1093/ecco-jcc/jjz150. [Epub ahead of print]

PMID:
31504350
10.

Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.

Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L.

Expert Opin Biol Ther. 2019 Sep 18:1-16. doi: 10.1080/14712598.2019.1666101. [Epub ahead of print]

PMID:
31498003
11.

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.

Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A; POPCUR study group.

Clin Gastroenterol Hepatol. 2019 Aug 27. pii: S1542-3565(19)30916-4. doi: 10.1016/j.cgh.2019.08.041. [Epub ahead of print]

PMID:
31470175
12.

Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.

Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F.

United European Gastroenterol J. 2019 Aug;7(7):908-913. doi: 10.1177/2050640619853448. Epub 2019 May 20.

13.

mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease.

Ungaro F, Garlatti V, Massimino L, Spinelli A, Carvello M, Sacchi M, Spanò S, Colasante G, Valassina N, Vetrano S, Malesci A, Peyrin-Biroulet L, Danese S, D'Alessio S.

Cells. 2019 Aug 18;8(8). pii: E924. doi: 10.3390/cells8080924.

14.

Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.

Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1673-1679.e1. doi: 10.1016/j.cgh.2018.10.032. Epub 2018 Oct 26. Review.

PMID:
31352970
15.

Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.

Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T.

Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):731-738. doi: 10.1080/17474124.2019.1645595. Epub 2019 Jul 26.

PMID:
31322440
16.

Ulcerative Colitis and Crohn's Disease Have the Same Burden and Goals for Treatment.

Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L.

Clin Gastroenterol Hepatol. 2019 Jul 10. pii: S1542-3565(19)30738-4. doi: 10.1016/j.cgh.2019.07.005. [Epub ahead of print] Review.

PMID:
31301452
17.

Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.

Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S.

Br J Clin Pharmacol. 2019 Oct;85(10):2244-2254. doi: 10.1111/bcp.14051. Epub 2019 Jul 31. Review.

PMID:
31269287
18.

Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.

D'Haens G, Rieder F, Feagan BG, Higgins PDR, Panes J, Maaser C, Rogler G, Löwenberg M, van der Voort R, Pinzani M, Peyrin-Biroulet L, Danese S; IOIBD Fibrosis Working Group.

Gastroenterology. 2019 Jun 26. pii: S0016-5085(19)41035-4. doi: 10.1053/j.gastro.2019.05.072. [Epub ahead of print]

PMID:
31254502
19.

Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer.

Tacconi C, Ungaro F, Correale C, Arena V, Massimino L, Detmar M, Spinelli A, Carvello M, Mazzone M, Oliveira AI, Rubbino F, Garlatti V, Spanò S, Lugli E, Colombo FS, Malesci A, Peyrin-Biroulet L, Vetrano S, Danese S, D'Alessio S.

Cancer Res. 2019 Aug 15;79(16):4196-4210. doi: 10.1158/0008-5472.CAN-18-3657. Epub 2019 Jun 25.

PMID:
31239267
20.

Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.

Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ.

Gastroenterology. 2019 Oct;157(4):1032-1043.e1. doi: 10.1053/j.gastro.2019.06.018. Epub 2019 Jun 19.

PMID:
31228441
21.

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L.

Gut. 2019 Oct;68(10):1893-1899. doi: 10.1136/gutjnl-2019-318448. Epub 2019 Jun 21. Review.

PMID:
31227590
22.

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.

D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S.

Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019. Review.

23.

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.

Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L; PROTECT-GETAID study group.

Clin Gastroenterol Hepatol. 2019 Jun 13. pii: S1542-3565(19)30642-1. doi: 10.1016/j.cgh.2019.05.060. [Epub ahead of print]

PMID:
31202984
24.

Comorbidities in inflammatory bowel disease: a call for action.

Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S.

Lancet Gastroenterol Hepatol. 2019 Aug;4(8):643-654. doi: 10.1016/S2468-1253(19)30173-6. Epub 2019 Jun 3. Review.

PMID:
31171484
25.

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.

Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID.

Aliment Pharmacol Ther. 2019 Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5.

PMID:
31165509
26.

Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?

Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S.

Curr Pharm Des. 2019;25(1):25-31. doi: 10.2174/1381612825666190313140811.

PMID:
31092171
27.

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.

Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L.

J Crohns Colitis. 2019 May 10. pii: jjz095. doi: 10.1093/ecco-jcc/jjz095. [Epub ahead of print]

PMID:
31076751
28.

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A.

J Crohns Colitis. 2019 Sep 27;13(10):1239-1247. doi: 10.1093/ecco-jcc/jjz088.

PMID:
31056693
29.

Psychological Functioning of Patients With Inflammatory Bowel Disease.

Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Allocca M, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G.

Inflamm Bowel Dis. 2019 Aug 20;25(9):e112. doi: 10.1093/ibd/izz082. No abstract available.

PMID:
31039252
30.

Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen.

Fiorino G, Peyrin-Biroulet L, Danese S.

Gastroenterology. 2019 Jun;156(8):2349-2351. doi: 10.1053/j.gastro.2019.04.029. Epub 2019 Apr 26. No abstract available.

PMID:
31034829
31.

Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses.

Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S.

Gastroenterology. 2019 Sep;157(3):647-659.e4. doi: 10.1053/j.gastro.2019.04.016. Epub 2019 Apr 20.

PMID:
31014995
32.

Detection and management of early stage inflammatory bowel disease: an update for clinicians.

Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S.

Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):547-555. doi: 10.1080/17474124.2019.1605291. Epub 2019 Apr 22.

PMID:
31007098
33.

Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease.

Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S.

Clin Gastroenterol Hepatol. 2019 Apr 14. pii: S1542-3565(19)30415-X. doi: 10.1016/j.cgh.2019.04.025. [Epub ahead of print] Review.

PMID:
30995529
34.

Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2019 May;49(9):1181-1187. doi: 10.1111/apt.15223. Epub 2019 Apr 1.

PMID:
30932219
35.

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.

Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L.

Am J Gastroenterol. 2019 Jun;114(6):874-883. doi: 10.14309/ajg.0000000000000183.

36.

Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11.

Ungaro F, Colombo P, Massimino L, Ugolini GS, Correale C, Rasponi M, Garlatti V, Rubbino F, Tacconi C, Spaggiari P, Spinelli A, Carvello M, Sacchi M, Spanò S, Vetrano S, Malesci A, Peyrin-Biroulet L, Danese S, D'Alessio S.

Int J Cancer. 2019 Oct 1;145(7):1913-1920. doi: 10.1002/ijc.32286. Epub 2019 Apr 9.

PMID:
30889293
37.

The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.

Al-Shamma H, Lehmann-Bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-Biroulet L, Adams J.

J Pharmacol Exp Ther. 2019 Jun;369(3):311-317. doi: 10.1124/jpet.118.254268. Epub 2019 Mar 14.

PMID:
30872391
38.

Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?

Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S.

Curr Pharm Des. 2019;25(1):7-12. doi: 10.2174/1381612825666190312113610.

PMID:
30864505
39.

Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.

D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S.

Immunotherapy. 2019 May;11(7):565-575. doi: 10.2217/imt-2018-0209. Epub 2019 Mar 12.

PMID:
30860423
40.

Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?

D'Amico F, Roda G, Peyrin-Biroulet L, Danese S.

Curr Pharm Des. 2019;25(1):19-24. doi: 10.2174/1381612825666190307165703.

PMID:
30848193
41.

Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?

Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-Biroulet L, Danese S.

Curr Pharm Des. 2019;25(1):47-56. doi: 10.2174/1381612825666190308100844.

PMID:
30848192
42.

Impact of inflammatory bowel diseases on working life: A French nationwide survey.

Le Berre C, Peyrin-Biroulet L, Buisson A, Olympie A, Ravel MH, Bienenfeld C, Gonzalez F.

Dig Liver Dis. 2019 Jul;51(7):961-966. doi: 10.1016/j.dld.2019.01.024. Epub 2019 Feb 11.

PMID:
30826278
43.

Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study.

Pineton de Chambrun G, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefasnescu C, Nancey S, Aubourg A, Serrero M, Peyrin-Biroulet L, Filippi J, Viennot S, Abitbol V, Boualit M, Boureille A, Moreau J, Buisson A, Roblin X, Nachury M, Zappa M, Lambert J, Bouhnik Y; GETAID-MICA study group.

J Crohns Colitis. 2019 Jan 25;13(Supplement_1):S616. doi: 10.1093/ecco-jcc/jjz045.

PMID:
30794285
44.

Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study.

Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L; CLEAN Study Group .

J Crohns Colitis. 2019 Sep 19;13(9):1121-1130. doi: 10.1093/ecco-jcc/jjz040.

PMID:
30785181
45.

Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials.

Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH.

BMJ Open. 2019 Jan 25;9(1):e024222. doi: 10.1136/bmjopen-2018-024222.

46.

Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S.

Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.

47.

Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"?

Le Berre C, Danese S, Peyrin-Biroulet L.

Dig Dis Sci. 2019 Feb 6. doi: 10.1007/s10620-019-05504-x. [Epub ahead of print] No abstract available.

PMID:
30725301
48.

A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials.

Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G.

J Crohns Colitis. 2019 Aug 14;13(8):1025-1035. doi: 10.1093/ecco-jcc/jjz022.

PMID:
30721964
49.

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.

Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L.

J Crohns Colitis. 2019 Aug 14;13(8):970-975. doi: 10.1093/ecco-jcc/jjz029.

PMID:
30698684
50.

Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients.

Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1399-1407. doi: 10.1093/ibd/izy400.

PMID:
30689871

Supplemental Content

Loading ...
Support Center